Infusion 51a's Press Releases
Our Portfolio Companies' Press Releases
Our Portfolio Companies' Press Releases
Our Portfolio Companies' Press Releases
Vivacitas Oncology Strengthens its Neuro-Oncology Board with World-Class Advisor Dr. Katherine Peters, MD, PhD, FAAN
Walnut Creek, CA, USA, January 31, 2022 – Vivacitas Oncology, Inc., a privately-held biopharmaceutical company focused on tough–to–treat cancers, continues to grow its Neuro-Oncology Advisory
Vivacitas Oncology to Present a Poster on AR-67 at the 3rd Annual Glioblastoma Drug Development Summit
Vivacitas will be attending and presenting a poster on its lead asset, AR-67 at the 3rd Annual Glioblastoma Drug Development Summit.
Dr. Erkut Borazanci, MD, Joins Vivacitas Oncology’s Pancreatic Medical Advisory Board
Vivacitas proudly announces that Dr. Erkut Borazanci, MD, has joined its Pancreatic Medical Advisory Board.
Vivacitas Oncology to present AR-67 at the Biotech Showcase Investor Conference
Vivacitas announces that its CEO, Mark Suseck, will present at the 2022 Biotech Showcase Conference, an investors event focused on biotechnology innovation that will be held virtually next January 10-12 and 17-19
Vivacitas Oncology welcomes Dr. Jai Grewal, MD, and expands its Neuro-Oncology Advisory Board
Vivacitas Oncology, Inc. is pleased to announce that Dr. Jai Grewal, MD, has agreed to become a new member of their distinguished Neuro-Oncology Advisory Board. Dr. Grewal will be joining Dr. Andrew Lassman, MD, MS, FAAN in the company’s Scientific Advisory Board.
Vivacitas Oncology Presents its New Neuro-Oncology Advisor, Dr. Andrew Lassman MD, MS, FAAN
WALNUT CREEK, CALIFORNIA, US, December 15, 2021 – Vivacitas Oncology, Inc. (“Vivacitas” or the “Company”), a privately-held oncology company focused on tough–to–treat cancers, is pleased